Latest news and press releases about MacroGenics, Inc. (MGNX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear...
Price
| Price | $4.08 |
| Market Cap | $259M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 6.05 |
| EV / EBITDA | -2.46 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -31.27% |
| Return on Invested Capital | -2.36% |
| Return on Assets | -4.22% |
| Gross Margin | 50.44% |
| Operating Margin | -24.30% |
| Net Margin | -8.70% |
Related companies: CLNN · CNTB · CNTX · COYA · IFRX · ORMP · OVID
Explore sector: Healthcare · Biotechnology
More sections of MGNX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks